Sarepta Therapeutics, Inc.

SRPT Healthcare Biotechnology

Sarepta Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $2.2 billion, up 15.6% from fiscal 2024. In the quarter to June 2026, revenue fell 34.3%, EPS fell 102.5%, free cash flow fell 14.5% and total debt fell 25.6%, each against the same quarter a year earlier. Revenue growth for ten consecutive years.

17.06 0.73 −4.10%
Market cap
$1.9B
P/E
0.0×
Fwd P/E
4.4×
Dividend yield
—
F-score
3/9
Altman Z
−0.97
Beneish M
−3.41
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
P/E ratio
0.00 35.27 0.00 0.00

+8 more quarters

P/S ratio
0.96 1.05 0.98 0.80
P/FCF ratio
25.27 21.11 0.00 0.00
P/Operating CF
9.61 (11.27) 16.42 (132.44)
P/B ratio
1.24 1.52 1.89 1.46
EV/Sales
1.04 1.17 0.97 0.91
EV/EBITDA
0.00 9,628.22 0.00 0.00
EV/FCF
27.28 23.66 (6.77) (5.68)
Current Ratio
4.42 4.63 2.32 2.95
Net Debt/EBITDA
2.59 0.50 0.27 (2.14)
Debt/Equity
0.55 0.56 0.73 0.78
Earnings Yield
(8.03%) 2.84% (33.15%) (14.22%)
Free Cash Flow Yield
3.96% 4.74% (14.64%) (20.13%)
Free Cash Flow per Share
1.86 (1.96) 1.27 (0.43)
Book value per Share
14.49 14.34 11.39 13.17
Free Cash Flow
196.52 (205.76) 127.48 (43.26)
EV/EBIT
0.00 0.00 0.00 0.00
Other line items

Show all line items

Columns are period end dates